• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种在效益-风险评估中使用狄利克雷分布统一多准则决策分析(MCDA)和随机多准则可接受性分析(SMAA)的简单方法。

A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment.

作者信息

Saint-Hilary Gaelle, Cadour Stephanie, Robert Veronique, Gasparini Mauro

机构信息

Dipartimento di Scienze Matematiche (DISMA) Giuseppe Luigi Lagrange, Politecnico di Torino, Torino, Italy.

Department of Biostatistics, Institut de Recherches Internationales Servier (IRIS), Suresnes, France.

出版信息

Biom J. 2017 May;59(3):567-578. doi: 10.1002/bimj.201600113. Epub 2017 Feb 10.

DOI:10.1002/bimj.201600113
PMID:28187230
Abstract

Quantitative methodologies have been proposed to support decision making in drug development and monitoring. In particular, multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) are useful tools to assess the benefit-risk ratio of medicines according to the performances of the treatments on several criteria, accounting for the preferences of the decision makers regarding the relative importance of these criteria. However, even in its probabilistic form, MCDA requires the exact elicitations of the weights of the criteria by the decision makers, which may be difficult to achieve in practice. SMAA allows for more flexibility and can be used with unknown or partially known preferences, but it is less popular due to its increased complexity and the high degree of uncertainty in its results. In this paper, we propose a simple model as a generalization of MCDA and SMAA, by applying a Dirichlet distribution to the weights of the criteria and by making its parameters vary. This unique model permits to fit both MCDA and SMAA, and allows for a more extended exploration of the benefit-risk assessment of treatments. The precision of its results depends on the precision parameter of the Dirichlet distribution, which could be naturally interpreted as the strength of confidence of the decision makers in their elicitation of preferences.

摘要

已提出定量方法来支持药物研发和监测中的决策制定。特别是,多标准决策分析(MCDA)和随机多标准可接受性分析(SMAA)是根据治疗在多个标准上的表现来评估药物效益风险比的有用工具,同时考虑了决策者对这些标准相对重要性的偏好。然而,即使是概率形式的MCDA也要求决策者精确确定标准的权重,而这在实践中可能难以实现。SMAA具有更大的灵活性,可以在偏好未知或部分已知的情况下使用,但由于其复杂性增加和结果的高度不确定性,它不太受欢迎。在本文中,我们提出了一个简单模型,作为MCDA和SMAA的推广,通过将狄利克雷分布应用于标准权重并使其参数变化。这个独特的模型既可以拟合MCDA也可以拟合SMAA,并允许对治疗的效益风险评估进行更广泛的探索。其结果的精度取决于狄利克雷分布的精度参数,该参数可以自然地解释为决策者在偏好确定方面的信心强度。

相似文献

1
A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment.一种在效益-风险评估中使用狄利克雷分布统一多准则决策分析(MCDA)和随机多准则可接受性分析(SMAA)的简单方法。
Biom J. 2017 May;59(3):567-578. doi: 10.1002/bimj.201600113. Epub 2017 Feb 10.
2
Incorporating Prior Data in Quantitative Benefit-Risk Assessments: Case Study of a Bayesian Method.将先验数据纳入定量获益-风险评估:贝叶斯方法的案例研究。
Ther Innov Regul Sci. 2024 May;58(3):415-422. doi: 10.1007/s43441-023-00611-4. Epub 2024 Jan 24.
3
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。
Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.
4
Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.两种方法将临床数据不确定性纳入药物获益-风险评估的多准则决策分析中。
Value Health. 2014 Jul;17(5):619-28. doi: 10.1016/j.jval.2014.04.008. Epub 2014 Jul 10.
5
Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.在一个假设情境中,基于多标准决策分析的药物效益-风险概况排名与直观排名之间的差异。
J Clin Pharm Ther. 2017 Feb;42(1):80-86. doi: 10.1111/jcpt.12486. Epub 2016 Dec 2.
6
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验
Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.
7
Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study.结合先进药物流行病学的实用多标准决策分析(MCDA)用于适应监管机构现实生活限制的药物效益风险评估:方法开发与案例研究
Ther Innov Regul Sci. 2016 Sep;50(5):620-631. doi: 10.1177/2168479016642812. Epub 2016 Jul 10.
8
Multicriteria Decision Analysis Characterization of Chemical Hazard Assessment Data Sources.多准则决策分析对化学危害评估数据源的特征描述。
Integr Environ Assess Manag. 2019 Nov;15(6):895-908. doi: 10.1002/ieam.4182. Epub 2019 Sep 13.
9
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.应用多标准决策分析(MCDA)简单评分法作为一种基于证据的卫生技术评估方法,用于评估新兴市场中的非专利药品(OPPs)。
Value Health Reg Issues. 2017 Sep;13:1-6. doi: 10.1016/j.vhri.2017.02.001. Epub 2017 May 11.
10
A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment.一个使用PrOACT-URL和BRAT框架进行结构化效益风险评估的案例研究。
Biom J. 2016 Jan;58(1):8-27. doi: 10.1002/bimj.201300248. Epub 2015 Jan 26.

引用本文的文献

1
A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment.多标准决策分析中用于药物效益-风险评估的各种聚合函数比较。
Stat Methods Med Res. 2022 May;31(5):899-916. doi: 10.1177/09622802211072512. Epub 2022 Jan 19.
2
From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs.从个体到群体偏好:离散选择模型和狄利克雷模型在治疗获益-风险权衡中的比较。
Med Decis Making. 2019 Oct;39(7):879-885. doi: 10.1177/0272989X19873630. Epub 2019 Sep 9.
3
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints.
一种用于具有连续疗效终点的高级I/II期临床试验的灵活设计。
Biom J. 2019 Nov;61(6):1477-1492. doi: 10.1002/bimj.201800313. Epub 2019 Jul 12.
4
A Bayesian approach for individual-level drug benefit-risk assessment.贝叶斯方法在个体药物获益-风险评估中的应用。
Stat Med. 2019 Jul 20;38(16):3040-3052. doi: 10.1002/sim.8166. Epub 2019 Apr 15.
5
A novel measure of drug benefit-risk assessment based on Scale Loss Score.一种基于量表损失评分的药物获益-风险评估新方法。
Stat Methods Med Res. 2019 Sep;28(9):2738-2753. doi: 10.1177/0962280218786526. Epub 2018 Jul 20.
6
Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis.采用贝叶斯随机多准则可接受性分析进行定期的获益-风险评估。
Contemp Clin Trials. 2018 Apr;67:100-108. doi: 10.1016/j.cct.2018.02.016. Epub 2018 Mar 2.